Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2004

View Archived Issues

Simvastatin dramatically improves survival in sepsis

Biocon Biopharmaceuticals expands product portfolio

Iseganan study in VAP stopped for safety reasons

New alpha-glucosidase inhibitors patented by Indian researchers

Novel MMP and/or TACE inhibitors under study at BMS

New hypoglycemic agents prepared and tested at Servier

Results of recent Lexapro pediatric study

Gepirone ER NDA deemed not approvable

GVAX vaccines development update

MediGene closes license agreement with U. Chicago for HSV technology

deCODE provides update on key programs

Positive opinion for Raptiva for psoriasis in Europe

Peregrine and Affitech achieve first milestone in collaboration

New overseas Femprox study

FDA lifts clinical hold on ocinaplon

Complete NDA submitted for Entereg in POI

First of two phase I studies for SNS-595

NICE recommends use of Elidel for atopic eczema

Arrow Therapeutics' RSV compound completes phase I

Preclinical progress in DOS-47 development program

European CHMP hands down positive opinion for Angiox

Glumetza NDA accepted for filing

Dipeptidyl-peptidase IV inhibitor delays the onset of diabetes in vivo

Novel monoclonal antibody promising against graft rejection

Novartis claims steryl sulfatase inhibitors with utility in acne therapy

New CCR1 antagonists and their use in rheumatoid arthritis, multiple sclerosis, etc.

NewBiotics presents PDF-activated prodrugs in a recent patent

Mechanism of antiinflammatory action of HS-378 explored

ACR-16 reported safe as adjunct therapy in patients with advanced PD

Stalevo reported safe and effective in improving motor fluctuations in PD patients

The role of resistin in insulin resistance and obesity

Preclinical and clinical evidence for the efficacy of transdermal rotigotine in PD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...